On February 3, 2019 AskAt reported that received a Notice of Allowance dated January 18, 2019 from the China National Intellectual Property Administration (CNIPA) in connection with Application No. 201510982848.3, a use patent for AskAt’s EP4 receptor antagonist for the treatment of cancer (Press release, AskAt, FEB 3, 2019, View Source [SID1234535036]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On February 1, 2019 Virometix reported the appointment of Anna Sumeray as Chief Executive Officer (Press release, Virometix, Feb 1, 2019, View Source [SID1234561508]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Virometix, a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases, reported the appointment of Anna Sumeray as Chief Executive Officer. She succeeds Arin Ghasparian, who will remain member of the Board of Directors. The Board of Directors wishes to thank Mr Ghasparian for his valuable contribution to the development of the Company, as Chief Executive Officer during the last six years.

Anna Sumeray brings more than 25 years of business leadership in the pharmaceutical and biotechnology industries. Ms. Sumeray currently serves as Managing Partner of Alacrita, a global life science consulting firm where she is responsible for the European operations and Commercial Practice. Prior to this, she was responsible for building the European entity for ARIAD pharmaceuticals from the ground up and achieved the successful launch of ponatinib in Europe across 17 countries.

Ms. Sumeray began her career in the life science industry at Amgen in business analysis and strategic planning, and moved to Novartis where she progressed through successive positions of increasing responsibility, including Head of Novartis Ophthalmics Global Business Development and Licensing and roles with P&L responsibility at Novartis Oncology in Finland, Novartis Oncology Germany and Nephrology and Transplantation at Sandoz.

She is also the owner of BioVault, an investment and consultancy company for start-up biotech companies and has been advising management of and making private investments in early-stage ventures for over 20 years.

A fluent speaker of several languages, Anna holds an MBA from INSEAD and a Bachelor of Sciences in biochemistry from the University of Birmingham.

Pierre Morgon, Chairman of the Board of Directors of Virometix commented: "We are delighted to welcome Anna as Chief Executive Officer of Virometix. Her 25 years’ of diverse experience across diverse types of organizations and her track record of developing international businesses will be key advantages for the expansion of Virometix."

Anna Sumeray, incoming Chief Executive Officer of Virometix, added, "I am joining the Virometix team with great enthusiasm and look forward to contributing my skills and experience to the advancement of the Virometix development activities and international partnering."

On February 1, 2019, 2019 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, reported that the company will participate and present at the following upcoming conferences (Press release, Iovance Biotherapeutics, FEB 1, 2019, View Source;p=RssLanding&cat=news&id=2385716 [SID1234533021]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

5th Annual Immuno-Oncology 360° conference in New York, February 6-8, 2019
Presenter: Maria Fardis, Ph.D., President and Chief Executive Officer
Session: Next Generation Cell Therapy Plenary
Title: Advancing the Development of Tumor Infiltrating Lymphocytes for Solid Tumors
Location: Crowne Plaza Times Square
Date/Time: February 8 at 11:10 a.m. EST

Guggenheim Healthcare Talks Idea Forum Oncology Day in New York on February 14, 2019
Date/Time: Thursday, February 14, 2019 at 3:00 p.m. EST
Location: The St. Regis New York Hotel
Webcast: A live and archived audio webcast of the presentation will be available in the Investors section at www.iovance.com.

ASCO-SITC Clinical Immuno-Oncology Symposium in San Francisco, February 28-March 2, 2019
Presenter: Amod Sarnaik, M.D. – H. Lee Moffitt Cancer Center
Poster Presentation Title: Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients previously treated with at least one prior systemic therapy
Abstract Number: 136
Date/Time: The poster will be presented on Friday, March 1, 2019 from 11:30 a.m.-1:00 p.m. and 5:30 p.m.-6:30 p.m. PST (Poster Session B, Board F1)
Location: San Francisco Marriott Marquis

On February 1, 2019 Bausch Health Companies Inc. (NYSE/TSX: BHC) reported that the Company will participate in two investor conferences in February and March (Press release, Valeant, FEB 1, 2019, View Source [SID1234533020]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Paul S. Herendeen, executive vice president and chief financial officer, and William Woodfield, vice president and treasurer, are scheduled to participate at the J.P. Morgan Global High Yield & Leveraged Finance Conference in Miami, Fla. on Feb. 25, 2019 at 11:40 a.m. EST.

Joseph C. Papa, chairman and chief executive officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the Barclays Global Healthcare Conference 2019 in Miami, Fla. on March 13, 2019 at 10:45 a.m. EDT.

A live webcast and audio archive of the Barclays event will be available on the Investor Relations page of the Bausch Health Companies Inc. web site at: View Source

On February 1, 2019 I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases, reported that it has entered into a memorandum of understanding (MOU) with Hong Kong-based Bio-Cancer Treatment International Limited (BCT) to jointly explore and investigate new therapeutic potentials for BCT’s arginine depletion therapy in autoimmune diseases and cancers (Press release, I-Mab Biopharma, FEB 1, 2019, View Source [SID1234533019]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

I-Mab Biopharma and Bio-Cancer Treatment International Announce Intention for Collaboration on Arginine Depletion Therapy and Biomarker Study, with Plans for I-Mab to Establish a Translational Medicine Lab in Hong Kong
I-Mab Biopharma and Bio-Cancer Treatment International Announce Intention for Collaboration on Arginine Depletion Therapy and Biomarker Study, with Plans for I-Mab to Establish a Translational Medicine Lab in Hong Kong
Under the terms of the MOU, I-Mab and BCT will work together to explore the potential of arginine depletion therapy in autoimmune diseases, as well as biomarkers in arginine and other immunologic targets in the tumor microenvironment for experimental cancer immunotherapy.

In conjunction with this development collaboration, I-Mab also plans to establish a translational medicine lab in Hong Kong to conduct exploratory biomarker work on BCT’s lead drug candidate, BCT-100, as well as a number of important assets in I-Mab’s own pipeline. Over the longer term, I-Mab will consider expanding the lab into a full-functioning R&D center in Hong Kong, taking advantage of the local scientific talent pool, clinical resources and government initiatives to encourage life sciences development.

"BCT is a biotech company with an established unique focus on targeting arginine metabolism to treat cancers and immune disorders. We are especially impressed by BCT’s ability to bring about collaborations among like-minded academic groups and clinician-scientists, to really understand, exploit and expand the therapeutic potential of something as vital as amino acid metabolism. We look forward to working closely with BCT to explore creating synergy with our pipelines. The partnership also provides I-Mab with an opportunity to set up a world-class translational medicine hub in Hong Kong, with further potential to develop clinical presence in Hong Kong," said Jielun Zhu, Chief Financial Officer of I-Mab.

"BCT is extremely honored to be working with I-Mab’s team of highly experienced biotech professionals in developing first-in-class biologics in autoimmune diseases and cancers to find ways to collaborate. The proposed biomarker study is very important to BCT both as precision medicine to identify cancer patients that would benefit the most from the BCT-100 treatment and also to apply the arginine depletion therapy to a wider patient population," said Derek Wong, CFO of BCT.